|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Darling G: The role of lymphadenectomy in
esophageal cancer. J Surg Oncol. 99:189–193. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kranzfelder M, Schuster T, Geinitz H,
Friess H and Buchler P: Meta-analysis of neoadjuvant treatment
modalities and definitive non-surgical therapy for oesophageal
squamous cell cancer. Br J Surg. 98:768–783. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chiu PW, Chan AC, Leung SF, Leong HT,
Kwong KH, Li MK, Au-Yeung AC, Chung SC and Ng EK: Multicenter
prospective randomized trial comparing standard esophagectomy with
chemoradiotherapy for treatment of squamous esophageal cancer:
early results from the Chinese University Research Group for
Esophageal Cancer (CURE). J Gastrointest Surg. 9:794–802. 2005.
View Article : Google Scholar
|
|
5
|
Bleiberg H, Conroy T, Paillot B, Lacave
AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F,
Collette L and Sahmoud T: Randomised phase II study of cisplatin
and 5-fluorouracil (5-FU) versus cisplatin alone in advanced
squamous cell oesophageal cancer. Eur J Cancer. 33:1216–1220. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Polee MB, Kok TC, Siersema PD, Tilanus HW,
Splinter TA, Stoter G and Van der Gaast A: Phase II study of the
combination cisplatin, etoposide, 5-fluorouracil and folinic acid
in patients with advanced squamous cell carcinoma of the esophagus.
Anticancer Drugs. 12:513–517. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hanawa M, Suzuki S, Dobashi Y, Yamane T,
Kono K, Enomoto N and Ooi A: EGFR protein overexpression and gene
amplification in squamous cell carcinomas of the esophagus. Int J
Cancer. 118:1173–1180. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mendelsohn J and Baselga J: The EGF
receptor family as targets for cancer therapy. Oncogene.
19:6550–6565. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vermorken JB, Trigo J, Hitt R, Koralewski
P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A and
Baselga J: Open-label, uncontrolled, multicenter phase II study to
evaluate the efficacy and toxicity of cetuximab as a single agent
in patients with recurrent and/or metastatic squamous cell
carcinoma of the head and neck who failed to respond to
platinum-based therapy. J Clin Oncol. 25:2171–2177. 2007.
|
|
10
|
Sobrero AF, Maurel J, Fehrenbacher L,
Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C,
Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kroning H,
Luppi G, Kisker O, Zubel A, Langer C, Kopit J and Burris HA III:
EPIC: phase III trial of cetuximab plus irinotecan after
fluoropyrimidine and oxaliplatin failure in patients with
metastatic colorectal cancer. J Clin Oncol. 26:2311–2319. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vincenzi B, Schiavon G, Silletta M,
Santini D and Tonini G: The biological properties of cetuximab.
Crit Rev Oncol Hematol. 68:93–106. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C,
Schueler A, Amellal N and Hitt R: Platinum-based chemotherapy plus
cetuximab in head and neck cancer. N Engl J Med. 359:1116–1127.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ilson DH: Esophageal cancer chemotherapy:
recent advances. Gastrointest Cancer Res. 2:85–92. 2008.
|
|
14
|
Cascone T, Morelli MP, Morgillo F, Kim WY,
Rodolico G, Pepe S, Tortora G, Berrino L, Lee HY, Heymach JV and
Ciardiello F: Synergistic anti-proliferative and pro-apoptotic
activity of combined therapy with bortezomib, a proteasome
inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs
in human cancer cells. J Cell Physiol. 216:698–707. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Meira DD, de Almeida VH, Mororo JS,
Nobrega I, Bardella L, Silva RL, Albano RM and Ferreira CG:
Combination of cetuximab with chemoradiation, trastuzumab or MAPK
inhibitors: mechanisms of sensitisation of cervical cancer cells.
Br J Cancer. 101:782–791. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tomblyn MB, Goldman BH, Thomas CR Jr,
Benedetti JK, Lenz HJ, Mehta V, Beeker T, Gold PJ, Abbruzzese JL
and Blanke CD; SWOG GI Committee. Cetuximab plus cisplatin,
irinotecan, and thoracic radiotherapy as definitive treatment for
locally advanced, unresectable esophageal cancer: a phase-II study
of the SWOG (S0414). J Thorac Oncol. 7:906–912. 2012. View Article : Google Scholar
|
|
17
|
Lee MS, Mamon HJ, Hong TS, Choi NC, Fidias
PM, Kwak EL, Meyerhardt JA, Ryan DP, Bueno R, Donahue DM, Jaklitsch
MT, Lanuti M, Rattner DW, Fuchs CS and Enzinger PC: Preoperative
cetuximab, irinotecan, cisplatin, and radiation therapy for
patients with locally advanced esophageal cancer. Oncologist.
18:281–287. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Meng X, Wang J, Sun X, Wang L, Ye M, Feng
P, Zhu G, Lu Y, Han C, Zhu S, Liao Z and Yu J: Cetuximab in
combination with chemoradiotherapy in Chinese patients with
non-resectable, locally advanced esophageal squamous cell
carcinoma: a prospective, multicenter phase II trail. Radiother
Oncol. 109:275–280. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Crosby T, Hurt CN, Falk S, Gollins S,
Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI,
Cunningham D, Blazeby J, Roy R, Maughan T and Griffiths G:
Chemoradiotherapy with or without cetuximab in patients with
oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised
trial. Lancet Oncol. 14:627–637. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lennerz JK, Kwak EL, Ackerman A, Michael
M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD,
Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ and Iafrate AJ:
MET amplification identifies a small and aggressive subgroup of
esophagogastric adenocarcinoma with evidence of responsiveness to
crizotinib. J Clin Oncol. 29:4803–4810. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kwak EL, Jankowski J, Thayer SP, Lauwers
GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR,
Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark
JW, Sgroi DC, Haber DA and Bell DW: Epidermal growth factor
receptor kinase domain mutations in esophageal and pancreatic
adenocarcinomas. Clin Cancer Res. 12:4283–4287. 2006. View Article : Google Scholar : PubMed/NCBI
|
